Abstract:Background: Vascular endothelial growth factor receptor 2 (VEGFR2) plays a key role in antiangiogenesis which has been an essential strategy for cancer treatment. We report the first-in-human study of AK109, a novel anti-VEGFR2 monoclonal antibody, to characterize the safety profile and pharmacokinetics/pharmacodynamics (PK/PD) properties, and explore the preliminary antitumor efficacy in patients with solid tumors.Patients and methods: This was a multicenter, open-label, phase I study, including dose escalation and dose expansion (NCT04547205). Patients with advanced cancers were treated 2 and 3 weekly with escalating doses of AK109. A 3 + 3 design was used to determine the maximum tolerated dose. Blood was sampled for PK/PD analysis. The primary endpoint was safety and recommended phase II dose (RP2D). Results: A total of 40 patients were enrolled. No dose-limiting toxicity was observed. However, 38 patients reported treatment-related adverse events (TRAEs); grade >3 TRAEs occurred in 10 patients. The most common TRAEs were proteinuria (n = 24, 60%), hypertension (n = 13, 32.5%), increased aspartate transaminase (n = 11, 27.5%), thrombopenia (n = 10, 25%), and anemia (n = 10, 25%). A total of 28 patients (70%) reported adverse events of special interest (AESIs). The most common AESIs were proteinuria (60%), hypertension (32.5%), and hemorrhage (32.5%), mainly including gum bleeding and urethrorrhagia. AK109 exhibited an approximately linear PK exposure with dose escalation at 2-12 mg/kg. PD analyses showed rapid target engagement. Among the 40 patients, 4 achieved partial response and 21 achieved stable disease with an objective response rate of 10% and a disease control rate of 62.5%. Based on the safety profile, the PK/PD profile, and preliminary antitumor activities, 12 mg/kg Q2W and 15 mg/kg Q3W were selected as RP2D.Conclusions: AK109 showed manageable safety profile and promising antitumor activity, supporting further clinical development in a large population.

Assessment of the Pre-Clinical Immunogenicity of a New VEGF Receptor Fc-fusion Protein FP3 with ELISA and BIACORE.

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

FP3: a Novel VEGF Blocker with Anti-Angiogenic and Anti-Tumor Effects.

Optimizing dosage regimen for FP 3 based on vascular normalization window monitored by ratio of Ang-1 to Ang-2

Antitumor Effect of FP3 on a Patient-Derived Tumor Tissue Xenograft Model of Rectal Carcinoma.

Antitumor Effect of FP3 in a Breast Cancer Xenograft Model.

Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys

Antitumor Effect of FP3 in a Patient-Derived Tumor Tissue Xenograft Model of Gastric Carcinoma Through an Antiangiogenic Mechanism.

First-in-human, Phase I Study of AK109, an Anti-Vegfr2 Antibody in Patients with Advanced or Metastatic Solid Tumors

PREPARATION OF RECOMBINANT PROTEIN OF EXTRACELLULAR LIGAND BINDING DOMAINS OF MOUSE VEGF RECEPTOR 2 AND ITS APPLICATION

Prokaryotic Expression of VEGF165 and Preliminary Screening of Anti-VEGF Hybridoma Cell Lines

Generation of Fusion Protein EGFRvIII-HBcAg and Its Anti-Tumor Effect in Vivo

In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates

Development of a Bridging ELISA for Detection of Antibodies Against ZV0203 in Cynomolgus Monkey Serum.

[Construction and Prokaryotic Expression of Recombinant Gene EGFRvIII HBcAg and Immunogenicity Analysis of the Fusion Protein].

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

[Antitumor Effect of EGFRvIII/HBcAg Recomibinant Vaccine on Murine Transplanted Tumor].

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

Nonclinical pharmacokinetics, pharmacodynamics and safety assessment of a FLT3L-Fc molecule for cancer immunotherapy

Preparation and characterization of human anti-EGFR scFv-protamine fusion protein

Pre-Clinical Studies of a Novel Bispecific Fusion Protein Targeting C3b and VEGF in Neovascular and Nonexudative AMD Models